Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue
Aims: Despite informative staging of patients with colorectal cancer, some patients with localised disease at diagnosis will develop recurrence or metastasis. Attempts to improve staging include sensitive detection of disseminated tumour cells in blood and bone marrow by reverse transcriptase polyme...
Saved in:
Published in | Molecular pathology Vol. 55; no. 3; pp. 156 - 163 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd and Association of Clinical Pathologists
01.06.2002
BMJ BMJ Publishing Group Ltd British Medical Journal Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Aims: Despite informative staging of patients with colorectal cancer, some patients with localised disease at diagnosis will develop recurrence or metastasis. Attempts to improve staging include sensitive detection of disseminated tumour cells in blood and bone marrow by reverse transcriptase polymerase chain reaction (RT-PCR). The results of this study have been considered in relation to the controversial results in the literature to elucidate the usefulness of cytokeratin 20 (CK20) RT-PCR to detect disseminated tumour cells further. Patients/Methods: Blood and bone marrow samples from 30 patients with colorectal cancer were studied by CK20 RT-PCR. Specificity was evaluated in 47 blood and 15 bone marrow samples from non-cancer controls. In addition, the expression of CK20 mRNA and protein was studied in normal and tumour colon tissue samples. Results: CK20 expression was detected in nine of 30 and nine of 19 of the blood and bone marrow samples from patients with colorectal cancer, respectively. In non-cancer control blood and bone marrow samples, CK20 expression was detected in 10 of 47 and four of 15, respectively. A difference between patient and control samples may be observed in terms of frequency of positive PCR tests. In tissue samples, CK20 mRNA expression was downregulated in tumour compared with normal colon tissue. Conclusions: CK20 expression was downregulated in tumour tissue compared with normal colon and a background expression of CK20 was seen in some control blood and bone marrow samples. Despite a lack of standardisation (which hampers comparison of studies), these results, together with other reports in the literature, suggest that CK20 may still be a suitable marker, but that background expression and threshold setting should be studied further. |
---|---|
Bibliography: | PMID:12032226 local:0550156 istex:D730C15F7B4BF5C0F58CA6004931852F4FBABA8C ark:/67375/NVC-6MVL2BNS-X href:molpath-55-156.pdf Correspondence to: Dr F Vlems, Department of Pathology, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands; f.vlems@pathol.azn.nl ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Correspondence to: Dr F Vlems, Department of Pathology, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands; f.vlems@pathol.azn.nl |
ISSN: | 1366-8714 1472-4154 |
DOI: | 10.1136/mp.55.3.156 |